Contrasting Insys Therapeutics (INSY) & The Competition
Insys Therapeutics (NASDAQ: INSY) is one of 294 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its competitors? We will compare Insys Therapeutics to related businesses based on the strength of its dividends, earnings, risk, institutional ownership, profitability, valuation and analyst recommendations.
Earnings and Valuation
This table compares Insys Therapeutics and its competitors revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Insys Therapeutics||$191.17 million||-$8.73 million||-37.36|
|Insys Therapeutics Competitors||$473.33 million||$171.79 million||-7.09|
Insys Therapeutics’ competitors have higher revenue and earnings than Insys Therapeutics. Insys Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Insider and Institutional Ownership
25.5% of Insys Therapeutics shares are owned by institutional investors. Comparatively, 51.2% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 67.9% of Insys Therapeutics shares are owned by insiders. Comparatively, 16.8% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
This table compares Insys Therapeutics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Insys Therapeutics Competitors||-5,461.13%||-388.46%||-43.02%|
Volatility and Risk
Insys Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500. Comparatively, Insys Therapeutics’ competitors have a beta of 6.61, meaning that their average share price is 561% more volatile than the S&P 500.
This is a summary of current recommendations for Insys Therapeutics and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Insys Therapeutics Competitors||721||3159||11766||262||2.73|
Insys Therapeutics currently has a consensus target price of $12.67, suggesting a potential upside of 35.62%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 29.22%. Given Insys Therapeutics’ higher possible upside, analysts clearly believe Insys Therapeutics is more favorable than its competitors.
Insys Therapeutics competitors beat Insys Therapeutics on 7 of the 12 factors compared.
Insys Therapeutics Company Profile
Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue. The Company markets Subsys through its field sales force focused on supportive care physicians in the United States. Subsys delivers a liquid fentanyl formulation in approximately 100, 200, 400, 600, 800, 1,200 and 1,600 micrograms (mcg) dosages. The Company’s lead dronabinol product candidate is Syndros, which is under review for approval at the Food and Drug Administration. In addition, the Company is evaluating sublingual spray, inhaled and intravenous formulations of dronabinol in preclinical studies.
Receive News & Ratings for Insys Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.